Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly's Antibody Reduces COVID-19 Risk by 80% in Nursing Homes

By Cory Renauer - Updated Jan 21, 2021 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Results of a clinical trial suggest pre-emptive treatment with bamlanivimab can prevent COVID-19 from spreading through nursing homes.

Nursing home residents who still haven't received a coronavirus vaccination can rest a little easier. Positive clinical-trial results released by Eli Lilly (LLY 2.10%) on Thursday suggest its bamlanivimab can reduce the risk of COVID-19 by 80% for nursing home residents. 

Bamlanivimab is an antibody that gloms onto the spiky part of the coronavirus responsible for COVID-19. The Food and Drug Administration has authorized it as a treatment for COVID-positive patients who are at risk of a severe infection, but not affected severely enough to require hospitalization.

Smiling scientist

Image source: Getty Images.

Results of the BLAZE-2 trial show it was highly effective at preventing COVID-19 from spreading through nursing homes that already had confirmed cases in their midst. The study enrolled 666 staff members and 299 residents who tested negative despite working or residing in facilities where the virus had already started spreading.

Overall, trial participants who received bamlanivimab were 57% less likely to show symptoms of COVID-19. Among the nursing home residents themselves, those randomized to receive bamlanivimab were 80% less likely to contract COVID-19 compared to residents in the same facility who received a placebo. There were four deaths attributed to COVID-19 among the group of 299 nursing home residents in the BLAZE-2 trial, and all four occurred among volunteers randomized to receive a placebo.

Since it received Emergency Use Authorization to treat patients who have already tested positive for COVID-19, hospitals haven't been eager to administer large intravenous infusions of bamlanivimab to COVID-positive patients who are healthy enough to send home. Today's clinical trial results could give Eli Lilly's treatment another chance to make an impact.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$313.46 (2.10%) $6.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.